Market Overview

GW Pharmaceuticals Shares Jump Following Price Target Raise

Share:
Related GWPH
Did The AAN Meeting Affect Biogen, PTC Therapeutics, GW Pharma Or Isis Pharma?
GW Pharmaceuticals plc Announces US Patent Allowance for Use of Cannabidivarin in Treating Epilepsy
GW Pharma initiates equity offering (Seeking Alpha)

In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.

The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.

Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.

Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.

Latest Ratings for GWPH

DateFirmActionFromTo
Apr 2015Leerink SwannMaintainsOutperform
Jul 2014Peel HuntDowngradesBuyHold
Jun 2014Piper JaffrayMaintainsOverweight

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color News Price Target Analyst Ratings

 

Related Articles (GWPH)

Around the Web, We're Loving...